“At Lonza, we continue to look for and develop science-backed ingredients to help brands create cleaner, more effective products that active consumers demand. TWK10® probiotic is a world-first for the sports nutrition market and true innovation. Originally isolated from fermented vegetables, specifically Taiwanese Kimchi, the unique patented TWK10® strain is the next generation of probiotics. It is scientifically proven to effectively modulate gut microbiota for sports endurance and performance benefits. TWK10® vegan probiotic also appears to support increased butyrate-producing bacteria in the gut for a positive increase in energy metabolism.”
“Fermented dairy products with active bacterial cultures are the typical source of many probiotics currently on the market. However, our extensive research exploring over 300 plant-derived probiotic strains revealed a unique strain with excellent survival rates. Currently, two human clinical trials have been completed on TWK10® probiotic, and studies have shown that it delivers significant benefits for fitness enthusiasts and active individuals, including increasing muscle endurance.”
Morristown, NJ (USA), September 16, 2020 – Lonza announces the launch of its L. plantarum (TWK10®) ingredient, a unique strain originally isolated from naturally fermented Taiwanese Kimchi. A novel probiotic designed to deliver sports nutrition benefits for both elite athletes and active consumers, the TWK10® brand is clinically shown to enhance endurance, improve body composition and energy levels. Licensed exclusively from Synbiotech for North America, the clean label, the vegan ingredient can be used in dietary supplements and in foods, with additional applications already in development. TWK10® probiotic is available now in North America.
Any athlete, any person, every advantage
Suitable for elite athletes, so-called “weekend warriors,” and active individuals alike, TWK10® probiotic helps improve athletic performance through greater energy harvesting. By enhancing muscle endurance, TWK10® probiotic allows consumers to train for longer. Derived from vegetables, TWK10® probiotic also enables brands to meet the increased consumer preference for vegan, plant-based sports nutrition products.
TWK10® probiotic is the latest addition to Lonza’s growing sports nutrition ingredient portfolio. The vegan MuscleGuard™ formulation comprises a unique blend of ingredients to offer clinically significant benefits for muscle strength, mass and activity. A sustainably-sourced phytoplankton ingredient, Oceanix™ brand offers clinically-studied benefits for sustained strength and power and short-term recovery. Carnipure® L-carnitine delivers both exercise and muscle recovery benefits. At the same time, UC-II® undenatured type II collagen improves joint health to further support active lifestyles
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Marketing Manager, Americas
Lonza Capsules & Health Ingredients
Tel +41 61 316 8929
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.